CA2929858C - Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis - Google Patents

Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis Download PDF

Info

Publication number
CA2929858C
CA2929858C CA2929858A CA2929858A CA2929858C CA 2929858 C CA2929858 C CA 2929858C CA 2929858 A CA2929858 A CA 2929858A CA 2929858 A CA2929858 A CA 2929858A CA 2929858 C CA2929858 C CA 2929858C
Authority
CA
Canada
Prior art keywords
gastrin
bone
receptor
ovx
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2929858A
Other languages
English (en)
French (fr)
Other versions
CA2929858A1 (en
Inventor
Irvin Mark MODLIN
Mark Kidd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CL Biosciences LLC
Original Assignee
CL Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52118000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2929858(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CL Biosciences LLC filed Critical CL Biosciences LLC
Publication of CA2929858A1 publication Critical patent/CA2929858A1/en
Application granted granted Critical
Publication of CA2929858C publication Critical patent/CA2929858C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2929858A 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis Active CA2929858C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907980P 2013-11-22 2013-11-22
US61/907,980 2013-11-22
PCT/US2014/066832 WO2015077572A1 (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis

Publications (2)

Publication Number Publication Date
CA2929858A1 CA2929858A1 (en) 2015-05-28
CA2929858C true CA2929858C (en) 2022-03-29

Family

ID=52118000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929858A Active CA2929858C (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis

Country Status (14)

Country Link
US (1) US10709714B2 (enExample)
EP (1) EP3071206B1 (enExample)
JP (1) JP6502939B2 (enExample)
KR (1) KR102254957B1 (enExample)
CN (1) CN106163527A (enExample)
AU (1) AU2014352875B2 (enExample)
BR (1) BR112016011727A2 (enExample)
CA (1) CA2929858C (enExample)
DK (1) DK3071206T3 (enExample)
ES (1) ES2870538T3 (enExample)
MX (1) MX2016006657A (enExample)
PL (1) PL3071206T3 (enExample)
RU (1) RU2693484C1 (enExample)
WO (1) WO2015077572A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881667B2 (en) 2018-10-30 2021-01-05 City University Of Hong Kong Method and composition for treating epilepsy
US11285161B2 (en) 2019-04-26 2022-03-29 City University Of Hong Kong Method and composition for treating mental disorder and pain associated with nerve damage
CN110935005A (zh) * 2019-11-19 2020-03-31 宁波大学 一种丙谷二肽的新用途
CN115770266B (zh) * 2023-01-30 2023-05-09 云南中医药大学 一种用于治疗绝经后骨质疏松的药物组合物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992437A (en) 1987-12-22 1991-02-12 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compounds and their pharmaceutical use
DK0411668T4 (da) 1989-08-04 1999-08-09 Merck Sharp & Dohme Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser
US5399565A (en) 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
WO1992011246A1 (en) 1990-12-25 1992-07-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzodiazepine derivative
JPH06509095A (ja) 1991-07-12 1994-10-13 ワーナー−ランバート・コンパニー パニック発作の治療に有用なコレシストキニン拮抗薬
JP3239364B2 (ja) * 1991-10-11 2001-12-17 ウェルファイド株式会社 骨粗鬆症治療薬およびジアゼピン化合物
WO1993012817A1 (en) 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
IL104853A (en) 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
MY128102A (en) 1993-02-17 2007-01-31 Chugai Pharmaceutical Co Ltd Indolin-2-one-derivatives
GB2282595A (en) 1993-08-25 1995-04-12 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
IT1261255B (it) 1993-09-09 1996-05-09 Rotta Research Lab Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
DE69637211T2 (de) 1995-12-11 2008-05-08 New England Medical Center Hospitals, Inc., Boston Test für und verwendungen von liganden von peptidhormonrezeptoren.
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5922883A (en) 1996-04-03 1999-07-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US20040001842A1 (en) 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
JP2002511066A (ja) 1997-05-12 2002-04-09 アフトン コーポレーション Ｃｃｋ−ｂ／ガストリン受容体に対する免疫原性組成物および腫瘍の治療方法
CN1216605C (zh) 1998-05-15 2005-08-31 埃弗顿有限公司 一种用于治疗胃泌素依赖性肿瘤的组合物
JP2002517396A (ja) 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
EP1156037B1 (en) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US20030191279A1 (en) 1999-08-27 2003-10-09 Goldstein Steven Wayne Urea derivatives useful as anticancer agents
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
CZ20021548A3 (cs) 1999-11-05 2002-10-16 Societe De Conseils De Recherches Et D'application Nové heterocyklické sloučeniny a jejich pouľití jako léků
AU3003701A (en) 1999-11-19 2001-05-30 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
AU2001253024A1 (en) 2000-04-10 2001-10-23 The General Hospital Corporation Diagnosis and treatment of gastrointestinal disease
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
AU2002252456A1 (en) 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
WO2002087620A1 (en) 2001-04-27 2002-11-07 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
WO2002092096A1 (en) 2001-05-11 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Antitumor agents
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
NZ532213A (en) 2001-11-13 2006-12-22 Black James Foundation Benzotriazepines as gastrin and cholecystokinin (CCK) receptor ligands
WO2003070236A2 (en) 2002-02-19 2003-08-28 Pharmacia Italia S.P.A. Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
DE10207037A1 (de) 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US20030049698A1 (en) 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
EP1675837A2 (en) 2003-03-28 2006-07-05 Janssen Pharmaceutica N.V. Benzo [1,2,5] thiadiazole compounds as cck2 modulators
GB0310865D0 (en) 2003-05-12 2003-06-18 Black James Foundation Gastrin and cholecystokinin receptor ligands
US7524837B2 (en) 2003-05-12 2009-04-28 Janssen Pharmaceutica N.V. Benzotriazapinone salts and methods for using same
WO2005007107A2 (en) * 2003-07-11 2005-01-27 University Of Massachusetts Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
CN1863781A (zh) 2003-08-08 2006-11-15 詹森药业有限公司 作为缩胆囊素2调节剂的2－(喹喔啉－5－基磺酰氨基)－苯甲酰胺化合物
WO2005090319A1 (en) 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7947833B2 (en) 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
KR20070057252A (ko) 2004-09-24 2007-06-04 얀센 파마슈티카 엔.브이. 설폰아미드 화합물
WO2006044352A2 (en) 2004-10-12 2006-04-27 Janssen Pharmaceutica N.V. Canine cholecystokinin 1 receptor materials and their use
EP1804785A2 (en) 2004-10-27 2007-07-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
WO2006052542A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
GB0425196D0 (en) 2004-11-15 2004-12-15 Black James Foundation Gastrin and cholecystokinin receptor ligands
AP2007004023A0 (en) 2004-12-17 2007-06-30 Pfizer Chromane derivatives useful as acid pump antagonists
JP4957250B2 (ja) 2005-01-19 2012-06-20 ゼリア新薬工業株式会社 抗腫瘍剤
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AU2006255047B2 (en) 2005-06-06 2011-09-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating sleep disorders
ES2332534T3 (es) 2005-06-14 2010-02-08 Raqualia Pharma Inc Derivados de bencimidazol sustituidos con cromano como antagonistas de la bomba de acidos.
ATE425791T1 (de) 2005-07-29 2009-04-15 Rottapharm Spa Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten
WO2007026218A2 (en) 2005-09-01 2007-03-08 Pfizer Japan Inc. Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists
WO2007031860A1 (en) 2005-09-15 2007-03-22 Pfizer Japan Inc. Indane substituted benzimidazoles and their use as acid pump inhibitors
WO2007072142A2 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Benzimidazole-5-carboxamide derivatives
JP4481344B2 (ja) 2005-12-19 2010-06-16 ラクオリア創薬株式会社 クロマン置換ベンゾイミダゾール誘導体及び酸ポンプ阻害剤としてのそれらの使用
CA2645007A1 (en) 2006-03-17 2007-09-27 Raqualia Pharma Inc. Chromane derivatives
CA2649000A1 (en) 2006-04-12 2007-10-18 Merck Patent Gesellschaft Mit Beschraenkter Haftung N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
FR2901472B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants
FR2901473B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide
US8466166B2 (en) 2006-09-21 2013-06-18 Raqualia Pharma Inc. Benzimidazole derivatives as selective acid pump inhibitors
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
WO2008059373A1 (en) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
WO2008114123A1 (en) 2007-03-21 2008-09-25 Raqualia Pharma Inc. Spiro benzimidazole derivatives as acid pump inhibitors
WO2008124518A1 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
WO2008124524A2 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
AU2008267444A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
RU2379043C2 (ru) 2007-08-02 2010-01-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы
WO2009020768A1 (en) 2007-08-07 2009-02-12 President And Fellows Of Harvard College Targeting the oncoprotein nucleophosmin
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
JPWO2010113458A1 (ja) 2009-03-31 2012-10-04 ゼリア新薬工業株式会社 １，５−ベンゾジアゼピン誘導体の製造法
WO2011004882A1 (ja) 2009-07-09 2011-01-13 ラクオリア創薬株式会社 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤
CA2775204A1 (en) 2009-09-24 2011-03-31 Centro Nacional De Investigaciones Oncologicas (Cnio) Fused imidazo [3, 2 - d] pyraz ines as pi3 kinase inhibitors
MX353257B (es) 2009-10-06 2018-01-05 Millennium Pharmaceuticals Inc Star Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
US9181414B2 (en) 2009-11-13 2015-11-10 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
WO2011063164A2 (en) 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
EP2560656A4 (en) 2010-04-23 2013-11-27 Kineta Inc ANTIVIRAL CONNECTIONS
CN103153096B (zh) 2010-08-12 2016-08-03 赛诺米克斯公司 提高甜味增强剂的稳定性的方法和包含稳定的甜味增强剂的组合物
EP2640379A4 (en) 2010-11-18 2014-08-13 Pier Pharmaceuticals LOW DOSED CANNABINOIDARY MEDICINES
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
AU2011343039B2 (en) 2010-12-14 2017-03-02 Electrophoretics Limited Casein kinase 1delta (CK1delta) inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013070725A1 (en) 2011-11-07 2013-05-16 Massachusetts Institute Of Technology Tungsten oxo alkylidene complexes for z selective olefin metathesis
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors

Also Published As

Publication number Publication date
JP2016538295A (ja) 2016-12-08
PL3071206T3 (pl) 2022-01-17
DK3071206T3 (da) 2021-05-25
JP6502939B2 (ja) 2019-04-17
CA2929858A1 (en) 2015-05-28
WO2015077572A1 (en) 2015-05-28
RU2693484C1 (ru) 2019-07-03
EP3071206A1 (en) 2016-09-28
KR20160088891A (ko) 2016-07-26
AU2014352875B2 (en) 2019-10-24
BR112016011727A2 (pt) 2017-08-08
MX2016006657A (es) 2016-10-12
AU2014352875A1 (en) 2016-05-26
KR102254957B1 (ko) 2021-05-25
ES2870538T3 (es) 2021-10-27
EP3071206B1 (en) 2021-02-17
CN106163527A (zh) 2016-11-23
RU2016124538A (ru) 2017-12-27
US20150148339A1 (en) 2015-05-28
AU2014352875A8 (en) 2016-06-30
US10709714B2 (en) 2020-07-14

Similar Documents

Publication Publication Date Title
Tabatabaei-Malazy et al. New horizons in treatment of osteoporosis
Kim et al. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss
Loncar et al. Metabolism and the heart: an overview of muscle, fat, and bone metabolism in heart failure
US7576053B2 (en) Methods and compositions for treating degenerative bone disorders
Lee et al. NPY regulation of bone remodelling
Salari Sharif et al. Current, new and future treatments of osteoporosis
China et al. Globular adiponectin reverses osteo-sarcopenia and altered body composition in ovariectomized rats
Joshua et al. Soluble guanylate cyclase as a novel treatment target for osteoporosis
Kok et al. Secondary osteoporosis in patients with an osteoporotic fracture
Israeli et al. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy
Tando et al. Hif1α is required for osteoclast activation and bone loss in male osteoporosis
CA2929858C (en) Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
Thomas Intermittent parathyroid hormone therapy to increase bone formation
Wang et al. The systemic bone protective effects of Gushukang granules in ovariectomized mice by inhibiting osteoclastogenesis and stimulating osteoblastogenesis
Schwarz et al. Status of drug development for the prevention and treatment of osteoporosis
Wei et al. Effect of whole body vibration therapy on circulating serotonin levels in an ovariectomized rat model of osteoporosis
Journé et al. Extracellular calcium downregulates estrogen receptor alpha and increases its transcriptional activity through calcium-sensing receptor in breast cancer cells
Abo-Elenin et al. An overview of osteoporosis and possible treatment approaches
Appelman-Dijkstra et al. Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches
Tsuji et al. Promotion of adipogenesis by an EP2 receptor agonist via stimulation of angiogenesis in pulmonary emphysema
Mohanty et al. Molecular mechanisms and treatment strategies for estrogen deficiency-related and glucocorticoid-induced osteoporosis: a comprehensive review
HK1230487A1 (en) Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
Di Bari et al. Vitamin D, Bone Metabolism, and Fracture Risk in Polycystic Ovary Syndrome. Metabolites 2021, 11, 116
Abo-Rayah et al. Forskolin Could Protect Against Flutamide-Induced Osteoporosis By Modulation of Serum Osteocalcin and Sclerostin In Rats
Fasipe et al. Osteoporosis Now and in the Future: The Role of Newer Emerging Agents in the Management of Osteoporotic Bone Diseases–A Review

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191115